Board Change and Notice of Results

22 September 2015

Silence Therapeutics plc

("Silence" or "the Company"),

Board Change and Notice of Results for the six months to 30th June 2015

LONDON - Silence Therapeutics plc, AIM: SLN, a leader in the development and delivery of novel RNA therapeutics, is pleased to announce that Chief Executive Officer, Ali Mortazavi, has today resumed his full time duties as he returns from compassionate leave. Following his return, Dr. Alastair Riddell, who acted as Executive Chairman during Ali's leave of absence has retired from the Board of Directors to concentrate on his other business interests.

Dr. Riddell has been succeeded by Dr. Stephen Parker, who has assumed the role of Non-Executive Chairman, effective immediately, having served the Company as a Non-Executive Director since November 2013.

Commenting on the announcement Ali Mortazavi said "On behalf of the Board I would like to acknowledge and thank Alastair for his contribution to the Company during his tenure and, particularly, in the past two months. On a personal note, I would also like to thank him for his loyalty and continual support during a very difficult personal time."

Dr. Stephen Parker said, "I am delighted to be appointed Chairman at an exciting stage in the Company's development. We have ambitious plans to become a leader in the emerging field of genetic medicine and I look forward to working with Ali Mortazavi, the Board and the senior team to deliver this."

Alastair Riddell commented, "It has been a great pleasure to contribute to the development and execution of the Company's strategic plan. I have enjoyed my time with Silence Therapeutics and wish the team well for the future."

Separately, the Company will announce its Interim Results for the six months to 30th June 2015 on Tuesday 29th September. 

Enquiries:

Notes to Editors

About Silence Therapeutics (www.silence-therapeutics.com)

Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need.